YO-01027  (Synonyms: Dibenzazepine; DBZ)

YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent γ-secretase inhibitor^[1][2].

IC50: 2.92±0.22 (Notch), 2.64±0.30 (APPL) nM^[1]

YO-01027 (0.25-10 μM, during 1-18 days) promotes iPSC generation from human neonatal keratinocytes^[2].
YO-01027 (2 μM, 3 days) does not affect p53 activity in OCT4, SOX2-transduced human keratinocytes^[2].
YO-01027 (10 μM, 3 days) promotes the proliferation of supporting cells (SCs) in cultured mouse cochleae^[3].
YO-01027 (10 μM, 3 days) generates new hair cell (HCs) and increases the HCs number in neonatal mouse cochleae^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

463.48

C₂₆H₂₃F₂N₃O₃

209984-56-5

二苯并氮卓 (GMP)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Groth C, et al. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. Mol Pharmacol. 2010 Apr;77(4):567-74.  [Content Brief]

  [2]. Ichida JK, et al. Notch inhibition allows oncogene-independent generation of iPS cells. Nat Chem Biol. 2014 Aug;10(8):632-639.  [Content Brief]

  [3]. Wu J, et al. Dibenzazepine promotes cochlear supporting cell proliferation and hair cell regeneration in neonatal mice. Cell Prolif. 2020 Sep;53(9):e12872.  [Content Brief]